Value-based pharmaceutical pricing, aimed at achieving better value for pharmaceutical spending and lowering drug prices, while maintaining innovation, is a concept that is gaining traction. In the U.S., prescription drug prices are set by pharmaceutical companies to maximize
Americans are dying from cancer because they either can’t afford the medications to treat it, or they have the money but refuse to bankrupt their families. Cancer is the second leading cause of death after heart disease in the U.S., claiming more than half a million lives each year. In 2016, it is estimated that 1,685,210 new cases of cancer will be diagnosed in the U.S., amounting to one new diagnosis every 30 seconds.